Chronic Kidney Disease in Lithium-Treated Older Adults: A Review of Epidemiology, Mechanisms, and Implications for the Treatment of Late-Life Mood Disorders

Drugs and Aging

Volumn 32, Issue 1, 2015, Pages 31-42

  Rej, Soham ^a,b   Elie, Dominique ^b,c   Mucsi, Istvan ^d   Looper, Karl J ^b,c   Segal, Marilyn ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; HYDROCHLOROTHIAZIDE; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; LITHIUM DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DRUG BLOOD LEVEL; DRUG MONITORING; GENE; GSK3BETA GENE; HEREDITY; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MOOD DISORDER; NEPHROGENIC DIABETES INSIPIDUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ACUTE KIDNEY INJURY; AGED; CHEMICALLY INDUCED; MIDDLE AGED; MOOD DISORDERS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; AGED; AGING; HUMANS; LITHIUM COMPOUNDS; MIDDLE AGED; MOOD DISORDERS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84925513736     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0234-9     Document Type: Review

References (133)

1. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44. doi:10.1111/bdi.12025.
2. Wilkinson D, Holmes C, Woolford J, Stammers S, North J. Prophylactic therapy with lithium in elderly patients with unipolar major depression. Int J Geriatr Psychiatry. 2002;17(7):619–22. doi:10.1002/gps.671.
3. Oquendo MA, Galfalvy HC, Currier D, Grunebaum MF, Sher L, Sullivan GM, et al. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry. 2011;168(10):1050–6. doi:10.1176/appi.ajp.2011.11010163.
4. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385–95. doi:10.1016/S0140-6736(09)61828-6.
5. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. doi:10.1136/bmj.f3646.
6. Grof P. Sixty years of lithium responders. Neuropsychobiology. 2010;62(1):8–16. doi:10.1159/000314305.
7. Juurlink DN, Mamdani MM, Kopp A, Rochon PA, Shulman KI, Redelmeier DA. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc. 2004;52(5):794–8. doi:10.1111/j.1532-5415.2004.52221.x.
8. Minay J, Paul R, McGarvey D, Savage G, Stevenson M, Fogarty D, et al. Lithium usage and renal function testing in a large UK community population; a case–control study. Gen Hosp Psychiatry. 2013;35(6):631–5. doi:10.1016/j.genhosppsych.2012.10.016.
9. Shulman KI, Rochon P, Sykora K, Anderson G, Mamdani M, Bronskill S, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ. 2003;326(7396):960–1. doi:10.1136/bmj.326.7396.960.
10. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58(1):85–91. doi:10.1176/appi.ps.58.1.85-a.
11. Strejilevich SA, Urtueta-Baamonde M, Teitelbaum J, Martino DJ, Marengo E, Igoa A, et al. Clinical concepts associated with lithium underutilization in the treatment of bipolar disorder [in Spanish]. Vertex. 2011;22(Suppl):3–20.
12. Crowe E, Halpin D, Stevens P. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008;337:a1530. doi:10.1136/bmj.a1530.
13. Rybakowski JK, Abramowicz M, Chlopocka-Wozniak M, Czekalski S. Novel markers of kidney injury in bipolar patients on long-term lithium treatment. Hum Psychopharmacol. 2013;28(6):615–8. doi:10.1002/hup.2362.
14. Olsson CL, Rippe B, Bendz H. A comparison of plasma cystatin C and plasma creatinine for the screening of renal function in lithium-treated patients. Clin Nephrol. 2010;74(2):132–40.
15. Hajhosseiny R, Khavandi K, Goldsmith DJ. Cardiovascular disease in chronic kidney disease: untying the Gordian knot. Int J Clin Pract. 2013;67(1):14–31. doi:10.1111/j.1742-1241.2012.02954.x.
16. Minutolo R, Lapi F, Chiodini P, Simonetti M, Bianchini E, Pecchioli S, et al. Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study. Clin J Am Soc Nephrol. 2014;9(9):1586–93. 10.2215/CJN.10481013.
17. Rej S, Abitbol R, Looper K, Segal M. Chronic renal failure in lithium-using geriatric patients: effects of lithium continuation versus discontinuation—a 60-month retrospective study. Int J Geriatr Psychiatry. 2013;28(5):450–3. doi:10.1002/gps.3841.
18. Rej S, Shulman K, Herrmann N, Harel Z, Fischer HD, Fung K, et al. Prevalence and correlates of renal disease in older lithium users: a population-based study. Am J Geriatr Psychiatry. 2014;22(11):1075–82. doi:10.1016/j.jagp.2014.01.015.
19. Rej S, Looper K, Segal M. The effect of serum lithium levels on renal function in geriatric outpatients: a retrospective longitudinal study. Drugs Aging. 2013;30(6):409–15. doi:10.1007/s40266-013-0068-x.
20. van Melick EJ, Meinders AE, Hoffman TO, Egberts TC. Renal effects of long-term lithium therapy in the elderly: a cross-sectional study. Int J Geriatr Psychiatry. 2008;23(7):685–92. doi:10.1002/gps.1961.
21. Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord. 2010;126(3):436–40. doi:10.1016/j.jad.2010.04.018.
22. Close H, Reilly J, Mason JM, Kripalani M, Wilson D, Main J, et al. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS One. 2014;9(3):e90169. doi:10.1371/journal.pone.0090169.
23. Bendz H, Schon S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int. 2010;77(3):219–24. doi:10.1038/ki.2009.433.
24. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47. doi:10.1001/jama.298.17.2038.
25. Lala SV, Sajatovic M. Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review. J Geriatr Psychiatry Neurol. 2012;25(1):20–5. doi:10.1177/0891988712436683.
26. Kilbourne AM, Goodrich DE, Lai Z, Post EP, Schumacher K, Nord KM, et al. Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: the Self-Management Addressing Heart Risk Trial (SMAHRT). J Clin Psychiatry. 2013;74(7):e655–62. doi:10.4088/JCP.12m08082.
27. Andreazza AC, Gildengers A, Rajji TK, Zuzarte PM, Mulsant BH, Young LT. Oxidative stress in older patients with bipolar disorder. Am J Geriatr Psychiatry. Epub 2014 May 28. doi:10.1016/j.jagp.2014.05.008.
28. Roxanas M, Grace BS, George CR. Renal replacement therapy associated with lithium nephrotoxicity in Australia. Med J Aust. 2014;200(4):226–8.
29. Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24(4):540–4. doi:10.1016/j.euroneuro.2014.01.002.
30. Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. The impact of modern treatment principles may have eliminated lithium-induced renal failure. J Psychopharmacol. 2014;28(2):151–4. doi:10.1177/0269881113516202.
31. Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults—a systematic review. J Geriatr Psychiatry Neurol. 2012;25(1):51–61. doi:10.1177/0891988712436690.
32. Hansen HE, Hestbech J, Sorensen JL, Norgaard K, Heilskov J, Amdisen A. Chronic interstitial nephropathy in patients on long-term lithium treatment. Q J Med. 1979;48(192):577–91.
33. Bendz H, Aurell M, Balldin J, Mathe AA, Sjodin I. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant. 1994;9(9):1250–4.
34. Hetmar O, Bolwig TG, Brun C, Ladefoged J, Larsen S, Rafaelsen OJ. Lithium: long-term effects on the kidney. I. Renal function in retrospect. Acta Psychiatr Scand. 1986;73(5):574–81.
35. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D’Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol. 2000;11(8):1439–48.
36. Lepkifker E, Sverdlik A, Iancu I, Ziv R, Segev S, Kotler M. Renal insufficiency in long-term lithium treatment. J Clin Psychiatry. 2004;65(6):850–6.
37. Head L, Dening T. Lithium in the over-65s: who is taking it and who is monitoring it? A survey of older adults on lithium in the Cambridge Mental Health Services catchment area. Int J Geriatr Psychiatry. 1998;13(3):164–71.
38. Wallin L, Alling C, Aurell M. Impairment of renal function in patients on long-term lithium treatment. Clin Nephrol. 1982;18(1):23–8.
39. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–7. doi:10.1053/j.ackd.2010.05.002.
40. Hetmar O, Clemmesen L, Ladefoged J, Rafaelsen OJ. Lithium: long-term effects on the kidney. III. Prospective study. Acta Psychiatr Scand. 1987;75(3):251–8.
41. Tyrer SP, Schacht RG, McCarthy MJ, Menard KN, Leong S, Shopsin B. The effect of lithium on renal haemodynamic function. Psychol Med. 1983;13(1):61–9.
42. Hardy BG, Shulman KI, Mackenzie SE, Kutcher SP, Silverberg JD. Pharmacokinetics of lithium in the elderly. J Clin Psychopharmacol. 1987;7(3):153–8.
43. Hewick DS, Newbury P, Hopwood S, Naylor G, Moody J. Age as a factor affecting lithium therapy. Br J Clin Pharmacol. 1977;4(2):201–5.
44. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010;11(16):2675–86. doi:10.1517/14656566.2010.485612.
45. Hagiwara S, McClelland A, Kantharidis P. MicroRNA in diabetic nephropathy: renin angiotensin, aGE/RAGE, and oxidative stress pathway. J Diabetes Res. 2013;2013:173783. doi:10.1155/2013/173783.
46. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721–8. doi:10.1016/S0140-6736(11)61516-X.
47. Sharma AN, Bauer IE, Sanches M, Galvez JF, Zunta-Soares GB, Quevedo J, et al. Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54C:289–98. doi:10.1016/j.pnpbp.2014.06.005.
48. Lotrich FE. Inflammatory cytokine-associated depression. Brain Res. Epub 2014 Jul 5. doi:10.1016/j.brainres.2014.06.032.
49. Huzayyin AA, Andreazza AC, Turecki G, Cruceanu C, Rouleau GA, Alda M, et al. Decreased global methylation in patients with bipolar disorder who respond to lithium. Int J Neuropsychopharmacol. 2014;17(4):561–9. doi:10.1017/S1461145713001569.
50. Che R, Yuan Y, Huang S, Zhang A. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol. 2014;306(4):F367–78. doi:10.1152/ajprenal.00571.2013.
51. Zoja C, Abbate M, Remuzzi G. Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. Nephrol Dial Transplant. Epub 2014 Aug 2. doi:10.1093/ndt/gfu261.
52. Rej S, Segal M, Low NC, Mucsi I, Holcroft C, Shulman K, et al. The McGill Geriatric Lithium-Induced Diabetes Insipidus Clinical Study (McGLIDICS). Can J Psychiatry. 2014;59(6):327–34.
53. Wilting I, Heerdink ER, Mersch PP, den Boer JA, Egberts AC, Nolen WA. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study. Bipolar Disord. 2009;11(4):434–40. doi:10.1111/j.1399-5618.2009.00699.x.
54. Grof P, Hux M, Dressler B, O’Sullivan K. Kidney function and response to lithium treatment. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4–6):491–4.
55. Lassen E, Vestergaard P, Thomsen K. Renal function of patients in long-term treatment with lithium citrate alone or in combination with neuroleptics and antidepressant drugs. Arch Gen Psychiatry. 1986;43(5):481–2.
56. Rej S, Margolese HC, Low NC. Diabetes insipidus secondary to combination atypical antipsychotic and lithium use in a bipolar disorder patient: a case report. Prim Care Companion CNS Disord. 2011;13(4):PCC.11l01138. doi:10.4088/PCC.11l01138.
57. Waller DG, Edwards JG, Polak A. Neuroleptics, lithium and renal function. Br J Psychiatry. 1985;146:510–4.
58. Vestergaard P, Amdisen A, Hansen HE, Schou M. Lithium treatment and kidney function. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand. 1979;60(5):504–20.
59. Bucht G, Wahlin A. Renal concentrating capacity in long-term lithium treatment and after withdrawal of lithium. Acta Med Scand. 1980;207(4):309–14.
60. Nora RM, Hariprasad MK, Beke AZ. Urinary osmolality in lithium and non-lithium treated psychiatric patients. J Clin Psychiatry. 1981;42(6):254.
61. Movig KL, Baumgarten R, Leufkens HG, van Laarhoven JH, Egberts AC. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry. 2003;182:319–23.
62. Rej S, Looper K, Segal M. Do antidepressants lower the prevalence of lithium-associated hypernatremia in the elderly? A retrospective study. Can Geriatr J. 2013;16(2):38–42. doi:10.5770/cgj.16.50.
63. Miller AL, Bowden CL, Plewes J. Lithium and impairment of renal concentrating ability. J Affect Disord. 1985;9(2):115–9.
64. Lokkegaard H, Andersen NF, Henriksen E, Bartels PD, Brahm M, Baastrup PC, et al. Renal function in 153 manic-depressive patients treated with lithium for more than five years. Acta Psychiatr Scand. 1985;71(4):347–55.
65. Schou M, Amdisen A, Thomsen K, Vestergaard P, Hetmar O, Mellerup ET, et al. Lithium treatment regimen and renal water handling: the significance of dosage pattern and tablet type examined through comparison of results from two clinics with different treatment regimens. Psychopharmacology (Berl). 1982;77(4):387–90.
66. Plenge P, Mellerup ET, Bolwig TG, Brun C, Hetmar O, Ladefoged J, et al. Lithium treatment: does the kidney prefer one daily dose instead of two? Acta Psychiatr Scand. 1982;66(2):121–8.
67. Waller DG, Edwards JG, Naik R, Polak A. Renal function during lithium treatment. Q J Med. 1984;53(211):369–79.
68. Presne C, Fakhouri F, Noel LH, Stengel B, Even C, Kreis H, et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int. 2003;64(2):585–92. doi:10.1046/j.1523-1755.2003.00096.x.
69. Jorgensen F, Larsen S, Spanager B, Clausen E, Tango M, Brinch E, et al. Kidney function and quantitative histological changes in patients on long-term lithium therapy. Acta Psychiatr Scand. 1984;70(5):455–62.
70. Smith RE, Helms PM. Adverse effects of lithium therapy in the acutely ill elderly patient. J Clin Psychiatry. 1982;43(3):94–9.
71. Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol. 2008;3(5):1324–31. doi:10.2215/CJN.01640408.
72. Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med. 1985;312(7):408–14. doi:10.1056/NEJM198502143120705.
73. Oakley PW, Whyte IM, Carter GL. Lithium toxicity: an iatrogenic problem in susceptible individuals. Aust N Z J Psychiatry. 2001;35(6):833–40.
74. Rej S, Senouci SI, Looper K, Segal M. Using hypernatraemic events to predict reduced renal function in elderly lithium patients: a brief report. Psychogeriatrics. 2013;13(1):25–8. doi:10.1111/j.1479-8301.2012.00433.x.
75. Trepiccione F, Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol. 2010;23(Suppl 16):S43–8.
76. Sim JH, Himmel NJ, Redd SK, Pulous FE, Rogers RT, Black LN, et al. Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus. PLoS One. 2014;9(7):e101753. doi:10.1371/journal.pone.0101753.
77. Kishore BK, Ecelbarger CM. Lithium: a versatile tool for understanding renal physiology. Am J Physiol Renal Physiol. 2013;304(9):F1139–49. doi:10.1152/ajprenal.00718.2012.
78. Sanches TR, Volpini RA, Massola Shimizu MH, Braganca AC, Oshiro-Monreal F, Seguro AC, et al. Sildenafil reduces polyuria in rats with lithium-induced NDI. Am J Physiol Renal Physiol. 2012;302(1):F216–25. doi:10.1152/ajprenal.00439.2010.
79. Trepiccione F, Pisitkun T, Hoffert JD, Poulsen SB, Capasso G, Nielsen S, et al. Early targets of lithium in rat kidney inner medullary collecting duct include p38 and ERK1/2. Kidney Int. 2014;86(4):757–67. doi:10.1038/ki.2014.107.
80. Trepiccione F, Capasso G, Nielsen S, Christensen BM. Evaluation of cellular plasticity in the collecting duct during recovery from lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 2013;305(6):F919–29. doi:10.1152/ajprenal.00152.2012.
81. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987;10(5):329–45.
82. Walker RJ, Leader JP, Bedford JJ, Gobe G, Davis G, Vos FE, et al. Chronic interstitial fibrosis in the rat kidney induced by long-term (6-mo) exposure to lithium. Am J Physiol Renal Physiol. 2013;304(3):F300–7. doi:10.1152/ajprenal.00182.2012.
83. Hetmar O, Povlsen UJ, Ladefoged J, Bolwig TG. Lithium: long-term effects on the kidney. A prospective follow-up study ten years after kidney biopsy. Br J Psychiatry. 1991;158:53–8.
84. Farshchian N, Farnia V, Aghaiani MR, Abdoli N. MRI findings and renal function in patients on lithium therapy. Curr Drug Saf. 2013;8(4):257–60.
85. Dennison U, Clarkson M, O’Mullane J, Cassidy EM. The incidence and clinical correlates of lithium toxicity: a retrospective review. Ir J Med Sci. 2011;180(3):661–5. doi:10.1007/s11845-011-0712-6.
86. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204–12. doi:10.1186/cc2872.
87. Waring WS. Management of lithium toxicity. Toxicol Rev. 2006;25(4):221–30.
88. Roose SP, Nurnberger JI, Dunner DL, Blood DK, Fieve RR. Cardiac sinus node dysfunction during lithium treatment. Am J Psychiatry. 1979;136(6):804–6.
89. Chen KP, Shen WW, Lu ML. Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry Clin Neurosci. 2004;58(1):25–9.
90. Kristoff CA, Hayes PE, Barr WH, Small RE, Townsend RJ, Ettigi PG. Effect of ibuprofen on lithium plasma and red blood cell concentrations. Clin Pharm. 1986;5(1):51–5.
91. Reimann IW, Diener U, Frolich JC. Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry. 1983;40(3):283–6.
92. Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003;64(11):1328–34.
93. Himmelhoch JM, Forrest J, Neil JF, Detre TP. Thiazide-lithium synergy in refractory mood swings. Am J Psychiatry. 1977;134(2):149–52.
94. Schou M, Amdisen A, Trap-Jensen J. Lithium poisoning. Am J Psychiatry. 1968;125(4):520–7.
95. Ghannoum M, Lavergne V, Yue CS, Ayoub P, Perreault MM, Roy L. Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retrospective cohort study. Clin Toxicol (Phila). 2010;48(1):34–41. doi:10.3109/15563650903344785.
96. Hansen HE, Pedersen EB, Amdisen A. Renal function and plasma aldosterone during acute lithium intoxication. Acta Med Scand. 1979;205(7):593–7.
97. Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al.; International Society for Bipolar Disorders. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559–95. doi:10.1111/j.1399-5618.2009.00737.x.
98. Collins N, Barnes TR, Shingleton-Smith A, Gerrett D, Paton C. Standards of lithium monitoring in mental health trusts in the UK. BMC Psychiatry. 2010;10:80. doi:10.1186/1471-244X-10-80.
99. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging. 2000;16(3):165–77.
100. van Melick EJ, Souverein PC, den Breeijen JH, Tusveld CE, Egberts TC, Wilting I. Age as a determinant of instability of serum lithium concentrations. Ther Drug Monit. 2013;35(5):643–8. doi:10.1097/FTD.0b013e31828f017d.
101. Kirkham E, Bazire S, Anderson T, Wood J, Grassby P, Desborough JA. Impact of active monitoring on lithium management in Norfolk. Ther Adv Psychopharm. 2013;3(5):260–5. doi:10.1177/2045125313486510.
102. Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, et al. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med. 2013;11:33. doi:10.1186/1741-7015-11-33.
103. Rodrigo C, de Silva NL, Gunaratne R, Rajapakse S, De Silva VA, Hanwella R. Lower estimated glomerular filtration rates in patients on long term lithium: a comparative study and a meta-analysis of literature. BMC Psychiatry. 2014;14:4. doi:10.1186/1471-244X-14-4.
104. Rybakowski JK, Abramowicz M, Drogowska J, Chlopocka-Wozniak M, Michalak M, Czekalski S. Screening for the markers of kidney damage in men and women on long-term lithium treatment. Med Sci Monit. 2012;18(11):CR656–60.
105. Kehoe RF. A cross-sectional study of glomerular function in 740 unselected lithium patients. Acta Psychiatr Scand. 1994;89(1):68–71.
106. Johnson FN, Amdisen A. The first era of lithium in medicine. An historical note. Pharmacopsychiatria. 1983;16(2):61–3. doi:10.1055/s-2007-1017450.
107. Jensen SB, Rickers H. Glomerular filtration rate during lithium therapy. A longitudinal study. Acta Psychiatr Scand. 1984;70(3):235–8.
108. Vestergaard P, Amdisen A. Lithium treatment and kidney function. A follow-up study of 237 patients in long-term treatment. Acta Psychiatr Scand. 1981;63(4):333–45.
109. Walker RG, Davies BM, Holwill BJ, Dowling JP, Kincaid-Smith P. A clinico-pathological study of lithium nephrotoxicity. J Chronic Dis. 1982;35(8):685–95.
110. Bendz H, Andersch S, Aurell M. Kidney function in an unselected lithium population. A cross-sectional study. Acta Psychiatr Scand. 1983;68(5):325–34.
111. Albert U, De Cori D, Aguglia A, Barbaro F, Lanfranco F, Bogetto F, et al. Lithium-associated hyperparathyroidism and hypercalcaemia: a case–control cross-sectional study. J Affect Disord. 2013;151(2):786–90. doi:10.1016/j.jad.2013.06.046.
112. Paul R, Minay J, Cardwell C, Fogarty D, Kelly C. Meta-analysis of the effects of lithium usage on serum creatinine levels. J Psychopharmacol. 2010;24(10):1425–31. doi:10.1177/0269881109104930.
113. Bendz H, Sjodin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant. 1996;11(3):457–60.
114. Hardy BG, Shulman KI, Zucchero C. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression. J Clin Psychopharmacol. 1997;17(1):22–6.
115. Rej S, Li BW, Looper K, Segal M. Renal function in geriatric psychiatry patients compared to non-psychiatric older adults: effects of lithium use and other factors. Aging Ment Health. 2014;18(7):847–53. doi:10.1080/13607863.2014.888536.
116. Aprahamian I, Santos FS, Dos Santos B, Talib L, Diniz BS, Radanovic M, et al. Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry. 2014;75(7):e672–8. doi:10.4088/JCP.13m08741.
117. de Groot T, Alsady M, Jaklofsky M, Otte-Holler I, Baumgarten R, Giles RH, et al. Lithium causes G2 arrest of renal principal cells. J Am Soc Nephrol. 2014;25(3):501–10. doi:10.1681/ASN.2013090988.
118. Bottinger EP. TGF-beta in renal injury and disease. Semin Nephrol. 2007;27(3):309–20. doi:10.1016/j.semnephrol.2007.02.009.
119. Zaidan M, Stucker F, Stengel B, Vasiliu V, Hummel A, Landais P, et al. Increased risk of solid renal tumors in lithium-treated patients. Kidney Int. 2014;86(1):184–90. doi:10.1038/ki.2014.2.
120. Rybakowski JK. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs. 2013;27(3):165–73. doi:10.1007/s40263-013-0040-7.
121. Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav. 2014;123C:3–16. doi:10.1016/j.pbb.2014.02.004.
122. Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY. Taiwan Bipolar Consortium. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 2014;370(2):119–28. doi:10.1056/NEJMoa1212444.
123. Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) report. PLoS One. 2013;8(6):e65636. doi:10.1371/journal.pone.0065636.
124. Consortium on Lithium Genetics, Hou L, Heilbronner U, Rietschel M, Kato T, Kuo PH, McMahon FJ, et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med. 2014;370(19):1857–9. doi:10.1056/NEJMc1401817#SA4.
125. Brandl EJ, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59(2):76–88.
126. Smyth LJ, Duffy S, Maxwell AP, McKnight AJ. Invited Review-genetic and epigenetic factors influencing CKD. Am J Physiol Renal Physiol. 2014;307(7):F757–76. doi:10.1152/ajprenal.00306.2014.
127. Forester BP, Streeter CC, Berlow YA, Tian H, Wardrop M, Finn CT, et al. Brain lithium levels and effects on cognition and mood in geriatric bipolar disorder: a lithium-7 magnetic resonance spectroscopy study. Am J Geriatr Psychiatry. 2009;17(1):13–23. doi:10.1097/JGP.0b013e318172b3d0.
128. Werneke U, Ott M, Renberg ES, Taylor D, Stegmayr B. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand. 2012;126(3):186–97. doi:10.1111/j.1600-0447.2012.01847.x.
129. Fahy S, Lawlor BA. Discontinuation of lithium augmentation in an elderly cohort. Int J Geriatr Psychiatry. 2001;16(10):1004–9.
130. Al Jurdi RK, Marangell LB, Petersen NJ, Martinez M, Gyulai L, Sajatovic M. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a “recovered” status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry. 2008;16(11):922–33. doi:10.1097/JGP.0b013e318187135f.
131. Knebel RJ, Rosenlicht N, Colllins L. Lithium carbonate maintenance therapy in a hemodialysis patient with end-stage renal disease. Am J Psychiatry. 2010;167(11):1409–10. doi:10.1176/appi.ajp.2010.10071009.
132. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry. 1997;54(1):9–13 (discussion 14–15).
133. Bendz H. Kidney function in a selected lithium population. A prospective, controlled, lithium-withdrawal study. Acta Psychiatr Scand. 1985;72(5):451–63.